These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 16503724

  • 21. Abciximab readministration.
    Orford JL, Holmes DR.
    Rev Cardiovasc Med; 2002; 3(2):67-70. PubMed ID: 12447149
    [Abstract] [Full Text] [Related]

  • 22. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Casterella PJ, Revenaugh JR, Burke JL, Pearson RR, Bair TL, May HT, Horne B, Anderson JL, Muhlestein JB.
    J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L.
    Am J Cardiol; 2004 Feb 15; 93(4):453-5. PubMed ID: 14969621
    [Abstract] [Full Text] [Related]

  • 26. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR, Riding D.
    Cardiol Rev; 2008 Feb 15; 16(4):213-8. PubMed ID: 18562812
    [Abstract] [Full Text] [Related]

  • 27. Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Vernon SM.
    Cardiol Clin; 2001 May 15; 19(2):235-52, vi. PubMed ID: 11407108
    [Abstract] [Full Text] [Related]

  • 28. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD, Poludasu S, Lazar J, Cavusoglu E.
    Catheter Cardiovasc Interv; 2009 Feb 01; 73(2):214-21. PubMed ID: 19156882
    [Abstract] [Full Text] [Related]

  • 29. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS, Jang IK.
    Am J Med; 2000 Aug 15; 109(3):224-37. PubMed ID: 10974186
    [Abstract] [Full Text] [Related]

  • 30. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, Chong BH, Scientific and Standardization Committee of The International Society On Thrombosis and Haemostasis.
    J Thromb Haemost; 2006 Mar 15; 4(3):678-9. PubMed ID: 16460451
    [No Abstract] [Full Text] [Related]

  • 31. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR, Salloum J, Sdringola S, Moustapha A, Ghani M, Hale S, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR.
    Am J Cardiol; 2001 Oct 15; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract] [Full Text] [Related]

  • 32. Outcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI.
    Dobesh PP, Lanfear SL, Abu-Shanab JR, Lakamp JE, Gowda S, Haikal MY.
    Ann Pharmacother; 2003 Oct 15; 37(10):1375-80. PubMed ID: 14519056
    [Abstract] [Full Text] [Related]

  • 33. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P, Roggerio A, Takada JY, Caribé PM, Avakian SD, Strunz CM.
    Sao Paulo Med J; 2016 Jan 19; 134(3):199-204. PubMed ID: 26786608
    [Abstract] [Full Text] [Related]

  • 34. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N, Salib H, Mascarenhas DA.
    J Invasive Cardiol; 2001 Jan 19; 13(1):56-8. PubMed ID: 11146690
    [Abstract] [Full Text] [Related]

  • 35. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, Tarducci R, Cosmi F, Baldassarre S, Burali A.
    J Am Coll Cardiol; 2006 Feb 07; 47(3):522-8. PubMed ID: 16458130
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS, Reich D, Mitre CA, Sharma SK.
    Am J Cardiol; 2001 Dec 01; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract] [Full Text] [Related]

  • 38. [GPIIb-IIIa inhibitors].
    Nurden P.
    Transfus Clin Biol; 2001 Apr 01; 8(2):114-22. PubMed ID: 11386043
    [Abstract] [Full Text] [Related]

  • 39. [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Albuquerque A.
    Rev Port Cardiol; 2001 Sep 01; 20(9):927-8. PubMed ID: 11763604
    [No Abstract] [Full Text] [Related]

  • 40. Eptifibatide and tirofiban: new preparations. Limited benefit.
    Prescrire Int; 2000 Oct 01; 9(49):135-8. PubMed ID: 11603412
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.